Toxicity reviews for a range of cannabinoids for use in inhalable consumer products

Client

A multinational manufacturer of consumer products.

Background

The client requested a series of urgent toxicity reviews for more than a dozen different cannabinoids, during the development of new inhalable consumer products. These cannabinoids included (-)-trans-delta-9-tetrahydrocannabinol (Δ9-THC) – the main psychoactive component of cannabis – cannabinol (CBN) and cannabidivarin (CBDV). Cannabidiol (CBD) had been evaluated by bibra for the client previously.

Project goals

To review the toxic potential of the target cannabinoids, with a focus on Expert Group opinions and relevant reviews, where available. Key areas of interest were any concerning toxicological data relevant to the inhaled chemicals, as well as their specific effects on mental wellbeing.

Approach

Bibra conducted searches for substance-specific toxicity data, with sources including our in-house toxicity database, TRACE, which identified Expert Group reports from the World Health Organization’s Expert Committee on Drug Dependence (WHO ECDD) and the European Food Safety Authority (EFSA). Key data were identified and summarised to provide the client with toxicological reviews for each cannabinoid of interest.

Project outcome

Bibra was able to provide the client with a toxicity review for each of the requested compounds, in a short timeframe. Any potential toxicological concerns were highlighted in each report.

Bibra project team

Richard Young
Beth O’Connell

 

Consumer Products More recent work Info about us Meet our team